171 related articles for article (PubMed ID: 37701337)
21. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
22. Case series of progressive familial intrahepatic cholestasis type 3: Characterization of variants in
Cheng J; Gong L; Mi X; Wu X; Zheng J; Yang W
Front Med (Lausanne); 2022; 9():962408. PubMed ID: 36569137
[TBL] [Abstract][Full Text] [Related]
23. Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis.
Overi D; Carpino G; Cristoferi L; Onori P; Kennedy L; Francis H; Zucchini N; Rigamonti C; Viganò M; Floreani A; D'Amato D; Gerussi A; Venere R; Alpini G; Glaser S; Alvaro D; Invernizzi P; Gaudio E; Cardinale V; Carbone M
JHEP Rep; 2022 Nov; 4(11):100556. PubMed ID: 36267871
[TBL] [Abstract][Full Text] [Related]
24. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
25. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration.
Arrese M; Pizarro M; Solís N; Koenig C; Accatino L
Biochem Pharmacol; 1995 Oct; 50(8):1223-32. PubMed ID: 7488238
[TBL] [Abstract][Full Text] [Related]
26. Progressive Familial Intrahepatic Cholestasis: A Study in Children From a Liver Transplant Center in India.
Mehta S; Kumar K; Bhardwaj R; Malhotra S; Goyal N; Sibal A
J Clin Exp Hepatol; 2022; 12(2):454-460. PubMed ID: 35535061
[TBL] [Abstract][Full Text] [Related]
27. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
Stättermayer AF; Halilbasic E; Wrba F; Ferenci P; Trauner M
J Hepatol; 2020 Sep; 73(3):651-663. PubMed ID: 32376413
[TBL] [Abstract][Full Text] [Related]
28. A novel compound heterozygous mutation in ABCB4 gene in a pedigree with progressive familial intrahepatic cholestasis 3: a case report.
Bai J; Li L; Liu H; Liu S; Bai L; Ning H; Song W; Zou H; Wang X; Chen Y; Zheng S; Duan Z
Ann Transl Med; 2021 Mar; 9(5):426. PubMed ID: 33842647
[TBL] [Abstract][Full Text] [Related]
29. Novel
Liu TF; He JJ; Wang L; Zhang LY
World J Clin Cases; 2022 Feb; 10(6):1998-2006. PubMed ID: 35317165
[TBL] [Abstract][Full Text] [Related]
30. Heterozygous ABCB4 mutations in children with cholestatic liver disease.
Gordo-Gilart R; Hierro L; Andueza S; Muñoz-Bartolo G; López C; Díaz C; Jara P; Álvarez L
Liver Int; 2016 Feb; 36(2):258-67. PubMed ID: 26153658
[TBL] [Abstract][Full Text] [Related]
31. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
32. ABCB4 Gene Aberrations in Human Liver Disease: An Evolving Spectrum.
Reichert MC; Lammert F
Semin Liver Dis; 2018 Nov; 38(4):299-307. PubMed ID: 30357767
[TBL] [Abstract][Full Text] [Related]
33. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
Almasio PL; Floreani A; Chiaramonte M; Provenzano G; Battezzati P; Crosignani A; Podda M; Todros L; Rosina F; Saccoccio G; Manenti F; Ballardini G; Bianchi FP; Scheuer PJ; Davies SE; Craxì A
Aliment Pharmacol Ther; 2000 Dec; 14(12):1645-52. PubMed ID: 11121914
[TBL] [Abstract][Full Text] [Related]
34. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
Degiorgio D; Crosignani A; Colombo C; Bordo D; Zuin M; Vassallo E; Syrén ML; Coviello DA; Battezzati PM
J Gastroenterol; 2016 Mar; 51(3):271-80. PubMed ID: 26324191
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic variability in Tunisian PFIC3 patients harboring a complex genotype with a differential clinical outcome of UDCA treatment.
Khabou B; Mahjoub B; Barbu V; Balhoudi N; Wardani A; Sfar MT; Fakhfakh F
Clin Chim Acta; 2018 Nov; 486():122-128. PubMed ID: 30036524
[TBL] [Abstract][Full Text] [Related]
36. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
Weber ND; Odriozola L; Ros-Gañán I; García-Porrero G; Salas D; Argemi J; Combal JP; Kishimoto TK; González-Aseguinolaza G
JHEP Rep; 2023 May; 5(5):100713. PubMed ID: 37096142
[TBL] [Abstract][Full Text] [Related]
37. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency.
Felzen A; van Wessel DBE; Gonzales E; Thompson RJ; Jankowska I; Shneider BL; Sokal E; Grammatikopoulos T; Kadaristiana A; Jacquemin E; Spraul A; Lipiński P; Czubkowski P; Rock N; Shagrani M; Broering D; Nicastro E; Kelly D; Nebbia G; Arnell H; Fischler B; Hulscher JBF; Serranti D; Arikan C; Polat E; Debray D; Lacaille F; Goncalves C; Hierro L; Muñoz Bartolo G; Mozer-Glassberg Y; Azaz A; Brecelj J; Dezsőfi A; Calvo PL; Grabhorn E; Hartleif S; van der Woerd WJ; Kamath BM; Wang JS; Li L; Durmaz Ö; Kerkar N; Jørgensen MH; Fischer R; Jimenez-Rivera C; Alam S; Cananzi M; Laverdure N; Ferreira CT; Guerrero FO; Wang H; Sency V; Kim KM; Chen HL; de Carvalho E; Fabre A; Bernabeu JQ; Zellos A; Alonso EM; Sokol RJ; Suchy FJ; Loomes KM; McKiernan PJ; Rosenthal P; Turmelle Y; Horslen S; Schwarz K; Bezerra JA; Wang K; Hansen BE; Verkade HJ;
JHEP Rep; 2023 Feb; 5(2):100626. PubMed ID: 36687469
[TBL] [Abstract][Full Text] [Related]
38. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
39. Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity.
De Masi R; Orlando S; De Donno A
Ann Clin Transl Neurol; 2019 Nov; 6(11):2347-2350. PubMed ID: 31568708
[TBL] [Abstract][Full Text] [Related]
40. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history.
Davit-Spraul A; Fabre M; Branchereau S; Baussan C; Gonzales E; Stieger B; Bernard O; Jacquemin E
Hepatology; 2010 May; 51(5):1645-55. PubMed ID: 20232290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
